BridgeBio (BBIO) Pharma announced positive topline results from CALIBRATE, its global Phase 3 study of encaleret in autosomal dominant hypocalcemia type 1. CALIBRATE was designed to study the efficacy and safety of encaleret, an investigational, orally-administered, negative allosteric modulator of the calcium-sensing receptor. The primary endpoint, defined as the proportion of participants randomized to receive encaleret achieving both serum calcium and urine calcium in the respective target ranges, was achieved by 76% of encaleret-treated participants compared to 4% for these same participants while on conventional therapy. Encaleret was well-tolerated with no discontinuations related to study drug
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Optimistic Buy Rating for BridgeBio Pharma: Promising Phase 3 Trial Results and Future Developments
- BridgeBio price target raised to $76 from $58 at BofA
- BridgeBio price target raised to $80 from $70 at H.C. Wainwright
- Positive Outlook for BridgeBio Pharma: Buy Rating Affirmed on Strong Phase 3 Trial Results and Strategic Market Positioning
- BridgeBio Pharma Announces Positive Phase 3 Study Results